Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Bendamustine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Acerta Pharma
- 12 Jun 2023 Planned End Date changed from 28 Feb 2024 to 28 Oct 2025.
- 12 Jun 2023 Planned primary completion date changed from 30 Apr 2023 to 28 Oct 2025.
- 12 Jun 2023 Status changed from recruiting to active, no longer recruiting.